Neovascular Age Related Macular Degeneration (ARMD) is a serious condition with limited treatment options, and this study evaluated the effectiveness and safety of Ranibizumab in patients.
A retrospective study included 126 eyes from 112 patients treated between 2006-2008, analyzing various factors affecting treatment results and side effects.
Results indicated that Ranibizumab was effective for up to 18 months, especially in patients with better baseline visual acuity, and was generally safe with few adverse reactions.